Çağlayan, D. Et Al. 2022. The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.. 2022 ASCO Annual Meeting , (Illinois, United States Of America), 13010.

Çağlayan, D., Koçak, M. Z., Geredeli, Ç., Tatlı, A. M., Eryılmaz, M. K., Sezgin Göksu, S., ... Araz, M.(2022). The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients. . 2022 ASCO Annual Meeting (pp.13010). Illinois, United States Of America

Çağlayan, Dilek Et Al. "The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.," 2022 ASCO Annual Meeting, Illinois, United States Of America, 2022

Çağlayan, Dilek Et Al. "The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.." 2022 ASCO Annual Meeting , Illinois, United States Of America, pp.13010, 2022

Çağlayan, D. Et Al. (2022) . "The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.." 2022 ASCO Annual Meeting , Illinois, United States Of America, p.13010.

@conferencepaper{conferencepaper, author={Dilek Çağlayan Et Al. }, title={The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.}, congress name={2022 ASCO Annual Meeting}, city={Illinois}, country={United States Of America}, year={2022}, pages={13010} }